Acute Antiemetic Efficacy and Safety of Dolasetron Mesylate, A 5-HT3 Antagonist, in Cancer Patients Treated with Cisplatin

Authors:
  • PCP. Cappelaere
    P. Cappelaere
  • MFM. Fabbro
    M. Fabbro
  • AFA. A. M.D. Fauser
    A. A. M.D. Fauser
  • TST. A. W. Splinter
    T. A. W. Splinter
  • MSM. Spielmann
    M. Spielmann
  • MSM. Schneider
    M. Schneider
  • BCB. M.D. Chevallier
    B. M.D. Chevallier
  • AGA. Goupil
    A. Goupil
  • JCJ. Chauvergne
    J. Chauvergne
  • PFP. Fargeot
    P. Fargeot
  • GPG. Prévot
    G. Prévot
Publisher website
Google Scholar
Abstract
Dolasetron mesylate (MDL 73,147EF), a new serotonin receptor (5-HT3) antagonist was administered to 164 cancer patients naive or nonnaive to chemotherapy, in single, rising doses of 10, 20, 30, 40, or 50 mg IV 15 minutes prior to an infusion of cisplatin. The severity of nausea and number of episodes of emesis were recorded during the 24-hour period following cisplatin administration. There were significant differences between the dose groups, sex, and naive and non-naive patients. There were also significant dolasetron dose-dependent differences for no emesis (p = .01), less than 3 emetic episodes (p = .01), time-to-onset of nausea (p = .04), and time-to-onset of emesis (p = .003). The severity of symptoms was greater for females, for patients with previous chemotherapy, and with shorter duration of cisplatin infusion. Adjustment for these variables and the study center reduced the associations between the dose of dolasetron mesylate and the outcome variables. The principal adverse events were headache (11%) and diarrhea (6%). Dolasetron mesylate was well tolerated; a single dose of 40 or 50 mg controlled acute nausea and vomiting induced by highly emetogenic chemotherapy in the majority, in particular in chemotherapy-naive and male patients. In conclusion, 50 mg and a larger dose merit study in controlled trials with stratification for sex and previous chemotherapy.